Emmanuel Antonarakis, MD

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Blue Earth Diagnostics
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    05/31/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Aikido Pharma
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    02/04/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Aadi Bioscience
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Tempus
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    04/01/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Novartis
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Bristol Myers-Squibb
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    11/09/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    02/28/2023
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    11/09/2023
    Relationship end date:
    04/30/2022

Pages

Return to PARPi: Precision Medicine in Advanced Prostate Cancer (2023)